recombinant human bone morphogenetic protein 4 (HS214) / Stemgen - LARVOL DELTA

Local delivery of hrBMP4 as an anticancer therapy in patients with recurrent glioblastoma: a first-in-human phase 1 dose escalation trial (EANO 2024) - "Local delivery of hrBMP4 in and around recurring glioblastoma is safe and well-tolerated. Three patients responded to the treatment. A complete response and long-term survival occurred in two of them."

Clinical • P1 data • Brain Cancer • CNS Tumor • Glioblastoma • Oncology • Solid Tumor • BMP4

A Dose Escalation Phase I Study Of Human- Recombinant Bone Morphogenetic Protein 4 Administrated Via CED In GBM Patients (clinicaltrials.gov) - P1 | N=15 | Completed | Sponsor: Stemgen | Active, not recruiting ➔ Completed

Trial completion • Brain Cancer • CNS Tumor • Glioblastoma • Oncology • Solid Tumor

Local delivery of hrBMP4 as an anticancer therapy in patients with recurrent glioblastoma: a first-in-human phase 1 dose escalation trial. (PubMed, Mol Cancer) - P1 | "Local delivery of hrBMP4 in and around recurring glioblastoma is safe and well-tolerated. Three patients responded to the treatment. A complete response and long-term survival occurred in two of them. This warrants further clinical studies on this novel treatment targeting glioblastoma CSCs."

Journal • P1 data • Brain Cancer • CNS Tumor • Glioblastoma • Oncology • Solid Tumor • BMP4

A Dose Escalation Phase I Study Of Human- Recombinant Bone Morphogenetic Protein 4 Administrated Via CED In GBM Patients (clinicaltrials.gov) - P1; N=15; Active, not recruiting; Sponsor: Stemgen; Recruiting ➔ Active, not recruiting; Trial completion date: Aug 2019 ➔ Mar 2021; Trial primary completion date: Jan 2019 ➔ Oct 2020

Clinical • Enrollment closed • Trial completion date • Trial primary completion date • Brain Cancer • Glioblastoma • Oncology • Solid Tumor